Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT-I10A Plus Standard Chemotherapy vs Placebo Plus Standard Chemotherapy as First-Line Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
CTR20191160Phase 3Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Sep 2019; status: completed.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20191160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191160.